Get the Stockscreener App
6.50
3.35%
-0.225
After Hours:
6.49
-0.010
-0.15%
Rocket Pharmaceuticals Inc stock is traded at $6.50, with a volume of 3.22M.
It is down -3.35% in the last 24 hours and up +5.69% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$6.725
Open:
$6.87
24h Volume:
3.22M
Relative Volume:
1.22
Market Cap:
$700.31M
Revenue:
-
Net Income/Loss:
$-258.08M
P/E Ratio:
-2.3636
EPS:
-2.75
Net Cash Flow:
$-202.32M
1W Performance:
-7.01%
1M Performance:
+5.69%
6M Performance:
-53.51%
1Y Performance:
-72.22%
1-Day Range:
$6.36
$6.87
1-Week Range:
$5.72
$7.39
52-Week Range:
$4.55
$26.98
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
6.50 | 753.09M | 0 | -258.08M | -202.32M | -2.75 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Cl - GuruFocus
Rocket Pharma's Gene Therapy Shows Promise in ACM Patients, Says Analyst - Benzinga
Rocket Pharmaceuticals (RCKT) Price Target Raised by Cantor Fitzgerald | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Price Target Maintained by Wedbush - GuruFocus
Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now? - MSN
Rocket Pharmaceuticals (RCKT) Sees Price Target Boost Amid Positive Trial Data | RCKT Stock News - GuruFocus
Chardan Ups Price Target on Rocket Pharmaceuticals to $46 From $45, Maintains Buy Rating - marketscreener.com
Chardan Ups Price Target for Rocket Pharmaceuticals (RCKT) | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Price Target Raised by Chardan Cap - GuruFocus
Rocket Pharma reports promising RP-A601 gene therapy trial results By Investing.com - Investing.com South Africa
Transcript : Rocket Pharmaceuticals, Inc.Special Call - marketscreener.com
Rocket Pharma reports promising RP-A601 gene therapy trial results - Investing.com
Rocket Pharmaceuticals Presents Preliminary Data From Phase 1 Clinical Trial of RP-A601 For PKP2 Arrhythmogenic Cardiomyopathy At 28th Annual Meeting Of The American Society Of Gene And Cell Therapy - marketscreener.com
Rocket Pharmaceuticals (RCKT) Phase 1 Trial Yields Promising Results | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy - BioSpace
Rocket Pharmaceuticals (RCKT) Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy - StreetInsider
Fanconi anemia Pipeline 2025: Groundbreaking Clinical - openPR.com
Research Analysts Set Expectations for RCKT FY2025 Earnings - Defense World
(RCKT) Investment Analysis - news.stocktradersdaily.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 7.5% Following Analyst Downgrade - Defense World
Wellington Management Group LLP Reduces Stake in Rocket Pharmace - GuruFocus
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $34.00 at Canaccord Genuity Group - Defense World
Canaccord Revises Rocket Pharmaceuticals (RCKT) Price Target Ami - GuruFocus
The Goldman Sachs Group Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $13.00 - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $51.00 at Scotiabank - Defense World
Promising Early-Stage Data and Strategic Adaptations Justify Buy Rating for Rocket Pharmaceuticals - TipRanks
RCKT: Scotiabank Lowers Price Target for Rocket Pharmaceuticals to $51 | RCKT Stock News - GuruFocus
Scotiabank Adjusts Price Target for Rocket Pharmaceuticals (RCKT - GuruFocus
Rocket Pharmaceuticals (RCKT) Maintains 'Buy' Rating Despite PT Reduction | RCKT Stock News - GuruFocus
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
22,645 Shares in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Purchased by Raymond James Financial Inc. - Defense World
JPMorgan Chase & Co. Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $44.00 - Defense World
Chardan Capital Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $45.00 - Defense World
Dimensional Fund Advisors LP Has $9.57 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (RCKT) Sees Price Target Adjustment by JP Morgan | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation - GuruFocus
Chardan Capital Lowers Price Target for RCKT to $45, Maintains B - GuruFocus
Rocket Pharmaceuticals (RCKT) Price Target Lowered by Goldman Sa - GuruFocus
Chardan Capital Lowers Price Target for RCKT to $45, Maintains Buy Rating | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy - Business Wire
Rocket Pharmaceuticals (RCKT) Price Target Lowered by Goldman Sachs | RCKT Stock News - GuruFocus
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus - sharewise
Rocket Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
JPMorgan Adjusts Price Target for Rocket Pharmaceuticals (RCKT) | RCKT Stock News - GuruFocus
Mariner LLC Takes $139,000 Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals: Q1 Earnings Snapshot - Norwalk Hour
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress - BioSpace
Rocket Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Post-Trade Analysis: Rocket Pharmaceuticals Inc (RCKT) Slides -19.62, Closing at 6.31 - DWinneX
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):